{"id":32189,"date":"2025-05-16T12:18:07","date_gmt":"2025-05-16T06:48:07","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=32189"},"modified":"2025-05-16T12:18:09","modified_gmt":"2025-05-16T06:48:09","slug":"imaavy-for-generalized-myasthenia-gravis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/imaavy-for-generalized-myasthenia-gravis","title":{"rendered":"J&J Enters gMG Arena with IMAAVY Approval, Challenging AstraZeneca, Argenx, and UCB"},"content":{"rendered":"\n

The FDA has approved Johnson & Johnson\u2019s anti-FcRn antibody, nipocalimab<\/strong>, for the treatment of generalized myasthenia gravis (gMG). This myasthenia gravis drug will be marketed under the name IMAAVY<\/strong>. Although J&J isn\u2019t the first to receive FDA approval for an FcRn-blocking antibody in this indication, the company is optimistic that IMAAVY\u2019s broad label will help secure a strong foothold in the FcRN inhibitors market<\/a> over time.<\/p>\n\n\n\n

With this approval, J&J enters a generalized myasthenia gravis competitive landscape alongside established players such as AstraZeneca<\/strong>, which markets SOLIRIS <\/strong>and ULTOMIRIS<\/strong>, as well as Argenx\u2019s VYVGART<\/strong> and UCB\u2019s RYSTIGGO and ZILBRYSQ<\/strong>. Like IMAAVY, both VYVGART and RYSTIGGO target the FcRn pathway, but have been on the market longer\u2014VYVGART since December 2021 and RYSTIGGO since June 2023.<\/p>\n\n\n\n

IMAAVY is approved for use in adults and adolescents aged 12 and older who test positive for anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies. These patients represent over 90% of the antibody-positive gMG population.<\/p>\n\n\n\n

This myasthenia gravis drug<\/a> functions by inhibiting FcRn, a protein that recycles IgG antibodies, including the pathogenic ones involved in autoimmune diseases. By blocking FcRn, IMAAVY significantly lowers levels of IgG autoantibodies while preserving other components of the immune system, according to clinical data.<\/p>\n\n\n\n

J&J, like others exploring the FcRn pathway, sees potential beyond gMG. Given IgG\u2019s involvement in a wide range of autoimmune disorders, the company envisions expanding IMAAVY\u2019s use across multiple future indications. J&J acquired IMAAVY as part of its $6.5 billion<\/strong> acquisition of Momenta Pharmaceuticals<\/strong> in 2020, with the FcRn blocker serving as the central focus of the deal.<\/p>\n\n\n\n

The approval is based on data from the pivotal and ongoing Vivacity-MG3 trial<\/strong>, which features the longest primary endpoint among registrational studies for FcRn blockers in adults with generalized myasthenia gravis. Key findings from the study include:<\/p>\n\n\n\n